The Effectiveness of Laser Treatment for Diabetic Retinopathy in Patients with Chronic Kidney Disease

ORIGINAL ARTICLE
Maria N. Ponomareva, Ivan M. Petrov, Evgeniya K. Gribanova

 
International Journal of Biomedicine. 2021;11(4):441-445.
DOI: 10.21103/Article11(4)_OA8
Originally published December 10, 2021

Abstract: 

Background: Panretinal photocoagulation (PRP) remains one of the effective methods of treatment in pre- and proliferative forms of retinopathy with high efficiency. The aim of this study was to investigate the efficacy of PRP depending on the somatic status, laboratory parameters, and the severity of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) and a history of diabetic retinopathy (DR).
Methods and Results: The study included 76 patients (50 women and 26 men) with T2D who underwent PRP for DR (152 eyes) using a VISULAS® 532s solid-state laser (ZEISS). The patients were divided into two groups depending on the severity of CKD. Group 1 (n=32, 64 eyes) included patients with CKD Stage 1, Group 2 (n=44, 88 eyes) included patients with CKD Stage 2. All patients underwent standard ophthalmological examination: visometry, tonometry, perimetry, biomicroscopy of the anterior segment of the eye and vitreous body, and fundus ophthalmoscopy. Thickness map of the retina was obtained using the RTVue-100 OCT (Optovue, Fremont, CA) EMM5 scan protocol and the Stratus OCT (Carl Zeiss Meditec, USA) radial scan protocol. Laboratory methods included a general blood test, PPG, FG, HbA1c, general urine analysis, and the assessment of blood levels of creatinine, ALT, and AST.
PRP was carried out according to the standard method, gradually, in three stages; the interval between the stages of laser treatment was 1 month. After laser treatment, all patients, regardless of the treatment stage, were prescribed topical Broxinac® (Bromfenac ophthalmic solution 0.09%). The dynamics of corrected visual acuity (CVA) parameters and the retinal thickness of the macular region were assessed before PRP and 3 months after the complex treatment.    
Multivariate analysis revealed a linear and nonlinear effect of lipid spectrum indicators (TC and LDL) on the formation of CL (crystalline lens) pathology. After treatment, a significant increase in CVA was noted in both study groups. The effectiveness of PRP coagulation depended on the severity of the CKD stage in T2D patients with DR.
Normalization of morphometric parameters of the macular region of the retina was noted in 93.8% of cases in Group 1 and in 86.4% of cases in Group 2. The decrease in the effectiveness of treatment was associated with the presence of macroangiopathy (CAD), concomitant diseases (CHF, AH and dyslipidemia), and CKD stage.
Conclusion: Prolonged administration of the non-steroidal, anti-inflammatory drug Bromfenacum® for a month after each stage of PRP is effective.

Keywords: 
diabetic retinopathy • chronic kidney disease • panretinal photocoagulation
References: 
  1. Papatheodorou K, Papanas N, Banach M, Papazoglou D, Edmonds M. Complications of Diabetes 2016. J Diabetes Res. 2016;2016:6989453. doi: 10.1155/2016/6989453. 
  2. Khalil SA, Megallaa MH, Rohoma KH, Guindy MA, Zaki A, Hassanein M, Malaty AH, Ismael HM, Kharboush IF, El Kafash DN, Sallam HN, Desouky IA. Prevalence of Chronic Diabetic Complications in Newly Diagnosed versus Known Type 2 Diabetic Subjects in a Sample of Alexandria Population, Egypt. Curr Diabetes Rev. 2019;15(1):74-83. doi: 10.2174/1573399814666180125100917.
  3. Wang W, He M, Gong X, Wang L, Meng J, Li Y, Xiong K, Li W, Huang W. Association of renal function with retinal vessel density in patients with type 2 diabetes by using swept-source optical coherence tomographic angiography. Br J Ophthalmol. 2020 Dec;104(12):1768-1773. doi: 10.1136/bjophthalmol-2019-315450. 
  4. Xu X, Gao B, Ding W, Wang Q, Zhang M, Tan T, Sun F, Lei J, Ji Q, Xu F. Retinal image measurements and their association with chronic kidney disease in Chinese patients with type 2 diabetes: the NCD study. Acta Diabetol. 2021 Mar;58(3):363-370. doi: 10.1007/s00592-020-01621-6. 
  5. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003 Jan;63(1):225-32. doi: 10.1046/j.1523-1755.2003.00712.x. 
  6. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984 Apr;102(4):527-32. doi: 10.1001/archopht.1984.01040030405011.
  7. Park HC, Lee YK, Cho A, Han CH, Noh JW, Shin YJ, Bae SH, Kim H. Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. PLoS One. 2019 Jul 29;14(7):e0220506. doi: 10.1371/journal.pone.0220506. 
  8. Coyne KS, Margolis MK, Kennedy-Martin T, Baker TM, Klein R, Paul MD, Revicki DA. The impact of diabetic retinopathy: perspectives from patient focus groups. Fam Pract. 2004 Aug;21(4):447-53. doi: 10.1093/fampra/cmh417.
  9. Beetham WP, Aiello LM, Balodimos MC, Koncz L. Ruby-laser photocoagulation of early diabetic neovascular retinopathy: preliminary report of a long-term controlled study. Trans Am Ophthalmol Soc. 1969;67:39-67. 
  10. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Sakharni Diabet. 2019;22(1S1):1-144.  [In Russian].
  11.  Bobykin EV. [Current approaches to the treatment of diabetic macular edema. A literature review]. Fyodorov Journal of Ophthalmic Surgery. 2019;(1):67-76. doi: 10.25276/0235-4160-2019-1-67-76. [Article in Russian].
  12. Mozherencov VP, Prokofyeva GL, Usova LA. [Ocular manifestations of diabetes mellitus]. Russian Journal of Clinical Ophthalmology. 2002;1:31. [Article in Russian].
  13. Palanker D, Blumenkranz MS. Panretinal photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol. 2012 Apr;153(4):780-1; author reply 781-2. doi: 10.1016/j.ajo.2012.01.001. 
  14. Distefano LN, Garcia-Arumi J, Martinez-Castillo V, Boixadera A. Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review. J Ophthalmol. 2017;2017:2407037. doi: 10.1155/2017/2407037. 
  15. Browning DJ, Stewart MW, Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol. 2018 Dec;66(12):1736-1750. doi: 10.4103/ijo.IJO_1240_18. 
  16. Au A, Singh RP. A multimodal approach to diabetic macular edema. J Diabetes Complications. 2016 Apr;30(3):545-53. doi: 10.1016/j.jdiacomp.2015.11.008. 

Download Article
Received August 4, 2021.
Accepted September 25, 2021.
©2021 International Medical Research and Development Corporation.